Methylation-driven silencing of thymosin β4 in blood cells predicted mortality in hepatitis B liver failure patients more accurately than the standard MELD scoring system.
Better than MELDThymosin β4 methylation status outperformed the MELD score — the clinical standard — for predicting 1-, 2-, and 3-month outcomes in early and mid-stage liver failure
What the researchers found
Hypermethylation (epigenetic silencing) of the thymosin β4 (Tβ4) gene was significantly more common in patients with acute-on-chronic hepatitis B liver failure (ACHBLF) compared to those with pre-liver failure, chronic hepatitis B, or healthy controls. Tβ4 mRNA expression showed the opposite pattern — lower in more severe disease. The 3-month mortality rate was significantly higher in patients with methylated Tβ4 than unmethylated.
Critically, Tβ4 methylation status outperformed the MELD score — the standard clinical tool — for predicting 1-, 2-, and 3-month disease incidence. Its predictive value was particularly strong for early and mid-stage liver failure, though not for advanced-stage disease.
Why it matters
Acute-on-chronic liver failure is a devastating condition with high mortality. The MELD score, currently the gold standard for predicting outcomes, has recognized limitations. Thymosin β4 is a peptide known for its roles in tissue repair, wound healing, and immune modulation. Discovering that its epigenetic silencing predicts poor outcomes better than MELD in early-stage disease could provide clinicians with a new biomarker for earlier, more accurate risk stratification — potentially enabling earlier intervention including liver transplant listing.
The numbers in context
n=317 total · 115 ACHBLF patients · 80 pre-ACHBLF · 86 CHB · 36 healthy controls · Tβ4 methylation predicted 1-, 2-, 3-month outcomes better than MELD · Higher 3-month mortality in methylated group
How the study worked
The study enrolled 115 patients with ACHBLF (further divided into early, mid, and advanced stages), 80 with pre-liver failure, 86 with chronic hepatitis B, and 36 healthy controls from a single university hospital. Tβ4 promoter methylation in peripheral blood mononuclear cells was assessed using methylation-specific PCR, and Tβ4 mRNA was quantified by real-time PCR. Prognostic value was compared against the MELD score for predicting 1-, 2-, and 3-month outcomes.
Who was studied
317 participants: 115 with ACHBLF, 80 with pre-ACHBLF, 86 with chronic hepatitis B, and 36 healthy controls
What this study cannot tell us
This is a single-center observational study, which limits generalizability. The sample sizes within subgroups (especially the 33 early-stage patients) are relatively small. The study only examined hepatitis B-related liver failure, so findings may not apply to other causes of liver failure. External validation in independent cohorts is needed before clinical adoption.
How to read the evidence
This is a single-center observational study with a reasonable total sample (317) but relatively small subgroups. The comparison to MELD is compelling, but external validation is needed. Evidence strength is moderate — promising for a biomarker discovery study but not yet ready for clinical implementation.
When this study was published
Published in 2023, this study represents recent research into peptide-based prognostic biomarkers for liver disease. Thymosin β4 has been studied for decades in other contexts, but its use as an epigenetic biomarker in liver failure is relatively novel.
The bigger picture
Thymosin β4 has been extensively studied as a therapeutic peptide for wound healing, cardiac repair, and neuroprotection. This study reveals a different angle — its epigenetic regulation as a disease biomarker. The finding that silencing of this tissue-repair peptide correlates with worse outcomes in liver failure is biologically intuitive: when the body's repair mechanisms are suppressed at the genetic level, recovery is less likely. This work sits at the intersection of peptide biology, epigenetics, and liver disease prognostication, and could eventually complement or improve upon existing clinical scoring systems.
Questions still open
- Could restoring thymosin β4 expression — through demethylating agents or direct peptide administration — improve outcomes in early-stage liver failure?
- Does Tβ4 methylation status predict outcomes in liver failure from other causes (alcohol, autoimmune, drug-induced)?
- Would combining Tβ4 methylation with the MELD score create a more accurate composite prognostic tool?
Common questions
What is thymosin β4 and why would its silencing matter in liver failure?
What is the MELD score and why is beating it significant?
Read the original research
Hypermethylation of thymosin β4 predicts a poor prognosis for patients with acute-on-chronic hepatitis B liver failure.
Hepatobiliary & pancreatic diseases international : HBPD INT, 22(4), 373-382
Citation
Wang, He; Yin, Yan-Ping; Wang, Zhen-Li; Qian, Yu; Fan, Yu-Chen; Liu, Hui-Hui; Wang, Kai. (2023). Hypermethylation of thymosin β4 predicts a poor prognosis for patients with acute-on-chronic hepatitis B liver failure.. Hepatobiliary & pancreatic diseases international : HBPD INT, 22(4), 373-382. https://doi.org/10.1016/j.hbpd.2022.08.005